Total Funding
77
80
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
43858
Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel drug delivery platform.
Leslie Gautam: Chief Business Officer- Miranda Toledano: Chief Executive OfficerPast Role: Trigr Therapeutics, Chief Operating Officer & Chief Financial Officer
About the Company
Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience and
networks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience.
